Such a solution does not force the DEA to make a particular decision but will provide transparency to the process so companies can better plan when regulatory decisions will be mad...
This lack of predictability in the timing of DEA scheduling decisions leads to unnecessary uncertainty in the drug development process and n...
H.R. 4299, the Improving Regulatory Transparency for New Medical Therapies Act, which Ranking Member Pallone and I introduced.
I yield back the balance of my time and, at this point, recognize the ranking member, Mr. Pallone, 5 minutes for an opening statement.
I would like to thank all of our witnesses for being here today, and I look forward to having a constructive discussion on these legislative...
This provision will get products to the market faster because innovators will be able to get clinical trials underway in a timely and predic...
It now takes, on average, well over a billion dollars and 14 years from the time a drug is discovered to the time of approval.
H.R. 4069, the Ensuring Patient Access and Effective Drug Enforcement Act, introduced by Reps. Marino and Blackburn, will facilitate greater...
Today's legislative hearing focuses on three bills designed to improve the predictability and transparency in Drug Enforcement Administratio...
H.R. 4299, which seeks to improve the transparency and consistency of DEA's scheduling of new FDA-approved drugs.
This lack of predictability in the timing of DEA's scheduling decisions leads to unnecessary uncertainty in the drug development process.